Cleared Traditional

K220911 - Elecsys CMV IgG (FDA 510(k) Clearance)

Oct 2022
Decision
197d
Days
Class 2
Risk

K220911 is an FDA 510(k) clearance for the Elecsys CMV IgG. This device is classified as a Enzyme Linked Immunoabsorbent Assay, Cytomegalovirus (Class II - Special Controls, product code LFZ).

Submitted by Roche Diagnostics (Indianapolis, US). The FDA issued a Cleared decision on October 12, 2022, 197 days after receiving the submission on March 29, 2022.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.3175.

Submission Details

510(k) Number K220911 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 29, 2022
Decision Date October 12, 2022
Days to Decision 197 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code LFZ — Enzyme Linked Immunoabsorbent Assay, Cytomegalovirus
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.3175

Similar Devices — LFZ Enzyme Linked Immunoabsorbent Assay, Cytomegalovirus

All 57
Architect CMV IgG
K220949 · Abbott Laboratories · Oct 2022
ADVIA Centaur CMV IgG and ADVIA Centaur CMV IgG Quality Control
K181213 · Siemens Healthcare Diagnostics, Inc. · Jul 2018
Elecsys CMV IgM
K163569 · Roche Diagnostics · Mar 2017
LIAISON® CMV IgG and LIAISON® CMV IgG Serum Control Set
K162969 · DiaSorin, Inc. · Jan 2017
ELECYS CMV IGM IMMUNOASSAY
K142133 · Roche Diagnostics · Oct 2014
ELECSYS PRECICONTROL CMV IGG, ELECSYS CMV IGG IMMUNOASSAY
K131605 · Roche Diagnostics · Feb 2014